Lupin announces completion of Pharmacovigilance Inspection by the U.S. FDA with No Observations

Global pharma major Lupin Limited (Lupin) today announced that the United States Food and Drug Administration (U.S. FDA) has completed a Post-marketing Adverse Drug Experience (PADE) inspection of the company's operations. The inspection closed with no observations.

The inspection was conducted at Lupin's global pharmacovigilance group based out of Mumbai from 20th March to 24th March, 2023. The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin's marketed products worldwide.

"As a pharmaceutical company, ensuring the safety of patients is our top priority. We are pleased to have successfully completed the FDA inspection for our Pharmacovigilance group with zero observations. This continues to demonstrate our unwavering commitment to compliance and patient safety," said Nilesh Gupta, Managing Director, Lupin.

Shares of Lupin Limited was last trading in BSE at Rs. 639.75 as compared to the previous close of Rs. 648.50. The total number of shares traded during the day was 17205 in over 932 trades.

The stock hit an intraday high of Rs. 654.95 and intraday low of 638.55. The net turnover during the day was Rs. 11165870.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 USFDA PhamacovigilanceInspection NoObservations